SIRT6 and metabolic dysfunction-associated steatohepatitis: Another study demonstrated that SIRT6 overexpression in liver reduced steatosis, inflammation, and fibrosis caused by a HFHF diet, indicating the SIRT6 activator may be a promising therapeutic direction for treating NASH by reducing oxidative stress and inflammation [97].